Texas Permanent School Fund boosted its position in shares of Haemonetics Corporation (NYSE:HAE) by 1.7% during the second quarter, Holdings Channel reports. The institutional investor owned 38,304 shares of the medical instruments supplier’s stock after buying an additional 653 shares during the period. Texas Permanent School Fund’s holdings in Haemonetics Corporation were worth $1,513,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. BlackRock Inc. boosted its stake in shares of Haemonetics Corporation by 48,854.9% in the first quarter. BlackRock Inc. now owns 6,289,728 shares of the medical instruments supplier’s stock worth $255,175,000 after buying an additional 6,276,880 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Haemonetics Corporation by 22.6% in the first quarter. Wellington Management Group LLP now owns 4,192,350 shares of the medical instruments supplier’s stock worth $170,084,000 after buying an additional 774,089 shares in the last quarter. Columbia Wanger Asset Management LLC purchased a new stake in shares of Haemonetics Corporation during the first quarter worth $23,786,000. Vanguard Group Inc. boosted its stake in shares of Haemonetics Corporation by 7.6% in the first quarter. Vanguard Group Inc. now owns 4,694,325 shares of the medical instruments supplier’s stock worth $190,449,000 after buying an additional 332,087 shares in the last quarter. Finally, Black Creek Investment Management Inc. boosted its stake in shares of Haemonetics Corporation by 24.8% in the first quarter. Black Creek Investment Management Inc. now owns 1,396,483 shares of the medical instruments supplier’s stock worth $56,655,000 after buying an additional 277,870 shares in the last quarter.

Haemonetics Corporation (NYSE HAE) opened at 42.60 on Wednesday. The stock has a 50 day moving average price of $40.42 and a 200-day moving average price of $40.22. Haemonetics Corporation has a 12-month low of $32.76 and a 12-month high of $43.74. The firm has a market cap of $2.24 billion, a price-to-earnings ratio of 553.25 and a beta of 0.90.

Haemonetics Corporation (NYSE:HAE) last announced its quarterly earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.02. The business had revenue of $211 million for the quarter, compared to the consensus estimate of $211.29 million. Haemonetics Corporation had a return on equity of 11.07% and a net margin of 0.48%. The business’s revenue was up .5% on a year-over-year basis. During the same quarter last year, the business posted $0.25 EPS. Equities analysts forecast that Haemonetics Corporation will post $1.61 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Texas Permanent School Fund Increases Position in Haemonetics Corporation (HAE)” was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/texas-permanent-school-fund-increases-position-in-haemonetics-corporation-hae/1493263.html.

HAE has been the subject of a number of research reports. BidaskClub cut Haemonetics Corporation from a “hold” rating to a “sell” rating in a research note on Friday, June 23rd. Zacks Investment Research cut Haemonetics Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, May 9th. TheStreet cut Haemonetics Corporation from a “b-” rating to a “c” rating in a research note on Monday, May 8th. Jefferies Group LLC reiterated a “buy” rating and issued a $42.00 price objective on shares of Haemonetics Corporation in a research note on Monday, May 8th. Finally, JMP Securities upgraded Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $50.00 price objective for the company in a research note on Thursday, July 13th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $40.86.

In related news, Director Ronald Merriman sold 17,471 shares of the firm’s stock in a transaction that occurred on Monday, May 22nd. The stock was sold at an average price of $40.33, for a total value of $704,605.43. Following the sale, the director now owns 24,925 shares of the company’s stock, valued at approximately $1,005,225.25. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 1.20% of the company’s stock.

About Haemonetics Corporation

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.